Clinical trials: Optical Neuritis
Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins…
- Trial name
- N-MOmentum LT (NCT06180278)
- Testing
- Blood tests, Inebilizumab
- Where
- 11 sites in United States, China and 5 more
- Volunteers
- 32 people
- Sponsor
- Amgen
Optic Neuritis
Linking Optic Nerve MRI and the Retinal Axonal Loss After Optic Neuritis
This study evaluates the length of optic nerve lesion on 3D-DIR sequence as an imaging biomarker predictive of retinal axonal loss and visual disability, 12 months after the occurence of a first clinical episode of optic neuritis.
- Trial name
- IRMANO (NCT03651362)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- University Hospital, Lille
MS (Multiple Sclerosis), NMO Spectrum Disorder
Imaging Evaluation of Central Nervous Autoimmune Diseases
Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people.
- Trial name
- NCT04822623
- Testing
- MRI
- Volunteers
- 300 people
- Sponsor
- Qilu Hospital of Shandong University
Neuromyelitis Optica
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
Neuromyelitis Optica (NMO) is a rare, devastating demyelinating disease of the central nervous system (CNS) that has different causes and treatments from the more common demyelinating disease multiple sclerosis (MS).
- Trial name
- A1AT for NMO (NCT02087813)
- Testing
- Alpha1-antitrypsin, methylprednisolone
- Where
- United States
- Sponsor
- Stanford University
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions.
- Conditions
- Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis
- Trial name
- NCT01623076
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder
Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
This is an uncontrolled, prospective, observational cohort study to assess the function of meningeal lymphatic drainage and dynamics of immune cells in patients with relapsing multiple sclerosis (RMS) or Neuromyelitis optica…
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System
- Trial name
- OMNISCIENCE (NCT05414487)
- Testing
- Ofatumumab
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Tianjin Medical University General Hospital
Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System
Pathologic-MRI Findings in Atypical IIDD
Our objective is to describe the pathologic and MRI findings in a series of patients with presumed demyelinating lesion of the central nervous system.
- Trial name
- IIDD (NCT03121105)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Neuromyelitis Optica Spectrum Disorder
A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)
This study will evaluate the safety and efficacy of MIL62 in patients with Neuromyelitis Optica Spectrum Disorder.
- Trial name
- NCT05314010
- Testing
- MIL62
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Beijing Mabworks Biotech Co., Ltd.
Neuromyelitis Optica Spectrum Disorder Attack
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage.
- Trial name
- ETA/PETA-NMOSD (NCT07410039)
- Testing
- Eculizumab+IVMP, IVIG+IVMP, IVMP
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders
The French Multiple Sclerosis Registry
OFSEP is an observational cohort of Multiple Sclerosis (MS) and related disorders set up in France. It aims to provide a major epidemiological tool on MS for the scientific community in France and abroad.
- Trial name
- OFSEP (NCT02889965)
- Where
- France
- Volunteers
- 54,000 people
- Sponsor
- Hospices Civils de Lyon
Optical Neuritis
Optical Coherence Tomography and Optic Neuritis (OCTON)
Optic neuritis (ON) can remain isolated or reveal a widespread and chronic disease of the central nervous system (CNS), a multiple sclerosis (MS) or, more rarely, a Devic's neuromyelitis optica (NMO) or a systemic disease.
- Trial name
- OCTON (NCT02573792)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neuromyelitis Optica Spectrum Disorder
Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital
Neuromyelitis Optica Spectrum Disorders (NMOSD) are a group of inflammatory demyelinating disorders of the central nervous system.
- Trial name
- NCT03819413
- Testing
- serum aquaporin 4 antibody (AQP-4-Ab), serum MOG antibody (anti-MOG), MRI brain, spine and orbit
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Assiut University
Neuromyelitis Optica Spectrum Disorder
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
This study is aimed to observe the effectiveness and safety of inebilizumab in the acute phase of neuromyelitis optica spectrum disorders.
- Trial name
- NCT05891379
- Testing
- Inebilizumab, oral immunosuppressant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xuanwu Hospital, Beijing
Optic Neuritis, Multiple Sclerosis
Visual Reconstitution Therapy After Optic Neuritis
Incomplete remission after an optic neuritis attack is not uncommon. Visual reconstitution therapy is a software-based approach that has been shown to substantially improve residual visual field deficits in patients with pre- and…
- Trial name
- VISION (NCT01274702)
- Testing
- Visual Reconstitutions Therapy, Saccadic Eye Movement Training
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Friedemann Paul
Myelitis, Transverse, Neuromyelitis Optica
A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis
This multi-center randomized controlled trial evaluates if the addition of intravenous immunoglobulin to standard treatment of corticosteroids improves outcome in children and adults with first episode of Transverse Myelitis of…
- Trial name
- STRIVE (NCT02398994)
- Testing
- Intravenous Methylprednisolone, Intravenous Immunoglobulin
- Where
- 18 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Neuromyelitis Optica Spectrum Disorder, NMOSD
A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab…
- Trial name
- SAkuraBonsai (NCT05269667)
- Testing
- Satralizumab 120 mg
- Where
- 3 sites in United States, South Korea and 1 more
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Optic Neuritis
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial
This clinical trial aims at preventing visual dysfunction and optic nerve degeneration associated with autoimmune optic neuritis by systemic i.v. administration of 33.000 IU erythropoietin over 3 days.
- Trial name
- TONE (NCT01962571)
- Testing
- Erythropoietin alfa
- Where
- 11 sites in Germany
- Volunteers
- 108 people
- Sponsor
- University Eye Hospital, Freiburg
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
Interleukin-2 (IL-2) is an essential cytokine for T-cell proliferation. Low-dose IL-2 has been shown to increase the proportion of regulatory T cells (Tregs), negatively regulate effector T cells such as Th17 and Tfh cells, and…
- Trial name
- NCT07809724
- Testing
- IL-2 (interleukin 2)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Neuromyelitis Optica Spectrum Disorders
An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
The diagnostic cohort study could will be use to verify the clinical performance of the AQP4 -immunoglobulin G detection kit and whether it has a good correlation with the clinical diagnosis results.
- Trial name
- NCT04388072
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Secondary Progressive Multiple Sclerosis
AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis
Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.
- Trial name
- NCT01228396
- Testing
- Hyperimmune caprine serum against HIV lysate
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Daval International Limited